About Array BioPharma
Array BioPharma is a company based in Boulder (United States) founded in 1998 was acquired by Pfizer in June 2019. The company has 1,020 employees. Array BioPharma operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Boulder, United States
- Employees 1,020
- Stage Public
- SectorsHealthcare
- Website arraybiopharma.com
- Social LinkedIn
- Acquired by Pfizer (Jun 2019)
- Legal Name Array Technologies, Inc.
Funding Insights of Array BioPharma
- Total Rounds 1
All 1 funding rounds of Array BioPharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2017 | – | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Array BioPharma
Array BioPharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Pfizer.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States |
Investor details for Array BioPharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Array BioPharma
1482 people are tracked at Array BioPharma (766 in leadership, 12 in board & advisors, 704 in team); the tracked headcount is 1,020.
| Name | Role | Group |
|---|---|---|
James Farrelly | VP - R&d Digital Platform Lead | Leadership |
John Harrold | Senior Director Of Pharmacometrics | Leadership |
Tomas Kaplan | Director - Commercial Strategy & Innovation (csi) | Leadership |
Sue Diviney | VP & Office of the Ombuds Lead | Leadership |
Roger Luebbe | Director/controller US Sterile Injectable Network | Leadership |
Andrew Muratore | VP & Assistant General Counsel, Mergers & Acquisitions, And Chief Counsel, Pfizer Ventures | Leadership |
Michael Comeaux | Director Product Integrity Corporate Compliance Global Security | Leadership |
Dave Boyd | Project Director Technology Support | Leadership |
Sriram Krishnaswami | Head, R&d Portfolio And Innovation | Leadership |
Michael Hovanyetz | Senior Director, Commercial Enterprise Solutions | Leadership |
Jon Ross | Director Site Supply Operations, North Creek | Leadership |
Torres Ernesto | Director, Physical Risk Mitigation, Global Security | Leadership |
Angela Wasunna Rwiliriza | Chief Counsel, Corporate Affairs, Policy And Privacy | Leadership |
William McDaniel | Director/team Leader, External Supply - Biotech Emerging Markets | Leadership |
Don Desantis | Director Salesforce Enablement | Leadership |
Luiz Arantes | Vice President U.s. Specialty Care Medical Lead | Leadership |
Veronica Garcia | Director, Business Relationship Manager | Leadership |
Waqas Mahmood | Global Procurement Manager (pakistan And Japan)- Business Engagement Partner & Chief Of Staff | Leadership |
Lidia Fonseca | EVP & Chief Digital & Technology Officer | Leadership |
Bhagyashree Khunte | Senior Director | Leadership |
1462 more people are available in the full profile.
Complete people profiles for Array BioPharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Array BioPharma
Array BioPharma is a publicly listed company on the NASDAQ with ticker symbol ARRY in USA, operating in the Electronic technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Nov 2000
- Listed onNASDAQ: ARRY
- Listed entityArray Technologies, Inc.
- Exchange sectorElectronic technology
- ISINUS04271T1007
- Share price$3.75 (-1.83% on the day) · 2026-10-08
- Market capitalisation$577.5M
- EPS (diluted, trailing year)$-0.97
- Volume (last session)5,531,966
Financials of Array BioPharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.28B | -$52.2M | $131.6M |
| 2024 | $915.8M | -$240.4M | $153.8M |
| 2023 | $1.58B | $137.2M | $271.9M |
| 2022 | $1.64B | $4.4M | $84.0M |
| 2021 | $853.3M | -$50.4M | $3.9M |
Detailed financial statements for Array BioPharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Array BioPharma
4 dated milestones of Array BioPharma across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Array BioPharma is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round.
- Exit Acquired by Pfizer.
Competitors of Array BioPharma
Array BioPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Array BioPharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Array BioPharma
Websites that share an audience with Array BioPharma (arraybiopharma.com).
Websites whose visitors overlap most with Array BioPharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| arqule.com | 100% | – | – | View details | |
| clovisoncology.com | 92% | – | – | View details | |
| amriglobal.com | 90% | 680.7K | – | View details | |
| biopharma.com | 88% | 1.7K | #9,262,866 | View details | |
| arenapharm.com | 84% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for Array BioPharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Array Biopharma
Complete news archive for Array BioPharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Array BioPharma
10 companies that operate in the same segment as Array BioPharma (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Array BioPharma
Array BioPharma was founded in 1998 and raised its 1st funding round 19 years after it was founded.
Array BioPharma is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
Array BioPharma has 1,020 employees.
Annual revenue of Array BioPharma is $1.28B as on Dec 31, 2025.
Array BioPharma is focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. It has 17 small molecules in pipeline including lead programs binimetinib, encorafenib and selumitinib all focussed on treatment of cancer. It also has fully integrated small molecule drug discovery platform. In 2014, company announced collaboration with biogen idec for discovery and development of novel kinase inhibitors for treatment of autoimmune disorders.
Array BioPharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Yes, Array BioPharma is publicly traded on NASDAQ under the ticker symbol ARRY.
Array BioPharma has 1 investor. Key investors include Pfizer.
Yes. Array BioPharma was acquired by Pfizer in June 2019.